tbuckley/cabot-search huggingface dataset:
A randomized phase I/II study of everolimus, irinotecan, and cetuximab versus capecitabine and oxaliplatin in gemcitabine-resistant patients with pancreatic cancer.
Authors: Jon Kroll Bjerregaard, Morten Ladekarl, Helle Anita Jensen, Lene Weber Vestermark, Katherina Podlekareva Farr, Per Pfeiffer
Journal: Journal of Clinical Oncology (2014)

e15238 Background: Little evidence exists on 2nd line therapy for gemcitabine resistant patients. The combination of oxaliplatin (Ox) and 5-FU has shown efficacy in small trials. We wanted to establish a tolerable dose of the combination of irinotecan, cetuximab and everolimus(ICE), and test it vs. the combination of capecitabine (Cap) and Ox in a randomized phase I/II setting. Methods: Patients were initially recruited in a 3+3 dose finding design with an expanded MDT cohort. After establishing MDT; patients were randomized between ICE (at MDT-1) and CapOx (Cap: 1250 mg/m2 BID and Ox: 70 mg/m2 q14d). Patients that progressed could cross-over to the other arm. (NCT01042028) Results: Between January 2010 and November 2012, 40 patients were recruited. Due to DLT toxicity (mainly mucositis) at dose level 1 of the phase I trial, the protocol was amended and patients were treated at dose level -1. Ten patients were safely treated at this dose. The final dose for everolimus was 2.5 mg q1d, for irinotecan 180 mg/m2 q14d and 500 mg/m2 q14d for cetuximab. At this dose level patients were randomized to either ICE or CapOx. Planned accrual was 90 patients, but due to the emergence of FOLFIRINOX and slow accrual, the study was terminated after randomization of 26 patients. One patient died before randomization. Median PFS for the ICE regime was 3.8 months (2.5-7.8), CapOx 3.5(1.7-5.3) p=0.72. Median OS for ICE was 7.7 (4.5-11.8) and for CapOx 4.5 (2.2-7.4) p=0.04. Six patients crossed from CapOx to ICE, and 3 patients from ICE to CapOx upon progression. RR for ICE was 25% (5-57), CapOx 29% (8-58). Toxicity grade 3+ in the ICE regime was acne-like-rash (20%), fatigue (16%), infection (16%) and emboli (12%). CapOx was associated with grade 3+ neuropathy (21%), emboli (14%), pain (21%) and PPE (14%). Conclusions: The triple combination of ICE displayed similar PFS but significantly increased OS compared to CapOx. Both regimes displayed cancer activity with acceptable response rates. Toxicity was manageable. Due to early termination no solid conclusions can be drawn. Selected patients may benefit from dual-targeted therapy. Clinical trial information: NCT01042028.
Psychosurgical Problems
Journal: JAMA (1952)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Anisocoria from jimsonweed
Authors: D. L. Savitt
Journal: JAMA (1986)

<h3>In Reply.—</h3> Since we submitted our article, which demonstrated no association between caffeine and benign breast disease, two new studies<sup>1,2</sup>reported a positive association. Dr Jacobson and Ms Liebman suggest that the inconsistencies in the results of the various studies may be due to inclusion of cases that had fibroadenoma or other unrelated lesions. We would like to point out that Lawson et al<sup>3</sup>included only patients with<i>biopsyproved</i>fibrocystic disease<sup>3,4</sup>and Marshall et al<sup>5</sup>included patients hospitalized because of a suspicion of breast cancer but with a<i>histologically</i>confirmed diagnosis of fibrocystic disease.<sup>5,6</sup> Although clearly there is a controversy surrounding this subject, it is not due to the absence of histological diagnoses in the negative studies.
Correction to: Anti-PD-1 antibodies as a salvage therapy for patients with diffuse large B cell lymphoma who progressed/relapsed after CART19/20 therapy
Authors: Chunmeng Wang, Fengxia Shi, Yang Liu, Yajing Zhang, Liang Dong, Xiang Li, Chuan Tong, Yao Wang, Liping Su, Jing Nie, Weidong Han
Journal: Journal of Hematology & Oncology (2021)
ABC trial (A011502): A randomized phase III double-blinded placebo controlled trial of aspirin as adjuvant therapy breast cancer.
Authors: Wendy Y. Chen, Eric P. Winer, Karla V. Ballman, Ann H. Partridge, Lisa A. Carey, Margaret Carvan, Carol Matyka, Kala Visvanathan, Banu Symington, Michelle D. Holmes
Journal: Journal of Clinical Oncology (2019)

TPS599 Background: In-vitro and in-vivo evidence suggest that aspirin may have an anti-tumor effect. Multiple epidemiologic studies have reported improved breast cancer survival among regular aspirin users compared to non-users. Pooled data from randomized trials of aspirin for cardiovascular disease have also reported a decreased risk of metastatic cancer among aspirin users. However, the exact benefits and risks for breast cancer survivors need to be confirmed in a randomized controlled trial. Even if the clinical effect were modest, the global impact would be substantial since aspirin is inexpensive and widely available. Methods: The primary objective is to compare the effect of 300 mg daily aspirin versus placebo upon invasive disease-free survival (iDFS) in high risk HER2 negative breast cancer patients. Secondary objectives include effects on overall survival, cardiovascular disease, toxicity, and adherence. A biospecimen repository will be created for correlative analyses including tumor collection at baseline and blood and urine samples and questionnaires assessing lifestyle factors associated with inflammation (pain, sleep, stress, and depression) at baseline and 2 years. Study design: Subjects will be randomized (1:1) to aspirin 300 mg vs placebo daily for 5 years in a double-blinded fashion. Stratification factors include hormone receptor (HR) status (positive vs negative), body mass index ( &lt; or ≥ 30 kg/m2), and stage (II vs III). Subjects will be followed every 6 six months while on study drug, then annually for 10 years. Accrual goal is 2936 patients to reach 381 iDFS events. We have 80% power to detect HR 0.75 assuming 5-year iDFS on placebo of 77%. Eligibility: Eligible subjects include patients aged 18-70 diagnosed with a primary invasive HER2 negative breast cancer. If HR positive, tumors need to be node positive and diagnosed within the past 10 years. If HR negative, tumors can be node positive or T2-4N0 within 18 months of diagnosis. Subjects who are currently anticoagulated or those with a prior history of GI bleeding, atrial fibrillation, or myocardial infarction are excluded. Subjects who regularly use aspirin (defined as ≥ 5 days per week) need to stop 30 days prior to enrollment. Updated accrual numbers will be given at the time of presentation. Clinical trial information: NCT02927249.
Cover Sheet for Index
Authors: Bruce Thiers, Dirk Elston, Detra Davis, Jack Lesher, Nikki Levin, Mary Spellman, Jeffrey Weinberg, Dermatologic Surgery, Clifford Perlis, Julie Prendiville, Frcpc Dermatopathology, John Maize, Social Media, Emily Altman, Robert Dellavalle, J Smith, Editors Emeritus, Richard Dobson, Jeffrey Bernhard, Calvin Mccall, Brett Sloan, James Solomon, Stephen Tyring, George Hruza, Pediatric Dermatology, Kelly Cordoro, Dermatopathology Carlson, Tammie Ferringer, Cyberdermatology Consultant, Daniel Siegel, Clara Kim, Bryan Anderson, Salvador Arias-Santiago, Trisha Beute, John Binhlam, Diana Bolotin, Markus Braun-Falco, Nooshin Brinster, Patrick Carrington, Zoe Draelos, Nananamibia Duffy, Laura Ferris, David Fivenson, Joel Gelfand, Camille Introcaso, Nathaniel Jellinek, Jonathan Kantor, Matthew Kanzler, Kevin Kia, Kenneth Linden, Jason Lott, Omar Lupi
Journal: Journal of the American Academy of Dermatology (2016)
The Use of Ferrokinetics in the Study of Experimental Anemia
Authors: Eun Woo Lee, James J. Kocsis, Robert Snyder
Journal: Environmental Health Perspectives (1981)

Erythropoietic cells in bone marrow are vulnerable to cytotoxic substances. There are three types of erythroid precursors: cells that can take up Fe but do not proliferate (reticulocytes), those that can take up Fe and proliferate (normoblasts and pronormoblasts), and those cells that do not take up Fe but can proliferate and differentiate into the erythroid cell line (ERC and stem cells). Each of these erythroid precursors requires a certain time before they emerge into the peripheral blood as mature red blood cells. By applying our understanding of ferrokinetics associated with erythropoiesis, it was possible to estimate a cytotoxic effect of chemicals on proliferating erythgroid precursors (pronormoblasts) in mice by measuring 24-hr 59Fe uptake in red blood cells 48 hr after treatment with chemicals. The effect of chemicals on pluripotent hemopoietic stem cells in mice was also estimated by measuring 24-hr 59Fe uptake 72 hr after treatment with chemicals. The validity of experimental schemes was tested using cytarabine, methotrexate, vinblastine, cyclophosphamide, and busulfan, which are known to act against specific cell types. Effects on pluripotent hemopoietic stem cells were tested with or without activation of stem cells in G0 into cell cycle. Applications of the 59Fe uptake method in the study of (1) benzene toxicity and (2) effect of pentobarbital on the toxic action of hydroxyurea and cytarabine are described. Proper application of the ferrokinetic characteristics of erythropoietic cells enables the establishment of a methodology which can be used to evaluate potential toxic effects of chemicals on erythroid precursor cells and pluripotent hemopoietic stem cells.
Book Review The Surgical Clinics of North America . Volume 13, Number 5. October, 1933. Chicago Number. Published by W. B. Saunders Company. Issued serially, one number every other month. Octavo of 254 pages with 93 illustrations. Per clinic year, February 1933 to December 1933. Price, Paper $12.00; Cloth, $16.00 net.
Journal: New England Journal of Medicine (1934)
Intensity of testing and invasive procedures
Authors: J. R. Crouse
Journal: JAMA (1996)

<h3>To the Editor.</h3> —The recent provocative articles dealing with the association between diagnostic testing and therapeutic interventions<sup>1-3</sup>highlight an issue of urgent importance that was discussed in each of these communications: although it is clear that diagnostic testing determines further procedures, it is unclear whether "more" or "less" diagnostic testing has a favorable risk-to-benefit ratio. It is obvious in the case of coronary angiography, for instance, that the procedure itself carries a definable risk, as does coronary artery bypass graft surgery. The long-term efficacy of bypass surgery, angioplasty, or both, for prolonging life is clear under only certain, very limited circumstances. It may be satisfactory to await an individual's first myocardial infarction (MI) before performing cardiac catheterization (unless, of course, the first infarct results in sudden death). A meaningful answer to this and related questions can ultimately be obtained only through a randomized clinical trial. We have found a
THE ORIGIN OF LIFE.
Journal: JAMA (1907)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 2138: Complex copy number profiles in oligodendroglioma associate with anaplastic morphology and recurrence
Authors: Steve Lowe, Scott Lindhorst, David Cachia, Adriana Olar
Journal: Cancer Research (2019)

Abstract Oligodendroglioma (O) comprises approximately 6% of all diffuse gliomas (DG) and is associated with favorable outcome. It is characterized by the presence of 1p/19q full arm co-deletion and concurrent IDH mutations. Despite a general favorable outcome selected patients with Os experience repeated radiological and histological progression. Copy number aberrations in Os may highlight profiles that correlate with patient's outcome. Thirty-three Os from the files of our institution were profiled by immunohistochemistry, sequencing, and SNP-microarray. Pertinent clinical, pathological, and radiological data was collected. Descriptive statistics and survival analyses were performed. Median age at initial diagnosis was 39 (range:19-80 years). Male to female ratio=1.2. All tumors were supratentorial with most common location the frontal lobe (21/33, 64%). Six tumors were anaplastic (WHO grade III). Nine patients experienced tumor recurrence, of which 5 experienced multiple recurrences. Only one patient died after 9.8 years from initial diagnosis. The median follow-up time = 2.5 years (range:0.01-23.6). 21/33(63%), 9/33(27%), and 3/33(0.09%) underwent subtotal, gross total resection, or biopsy respectively. 48%(16/33) patients received chemotherapy and/or radiation therapy at initial diagnosis. Most tumors (28; 85%) had additional copy number aberrations most commonly involving chromosomes 11q, 12q, 9p, 4q, 3p, 11p. Chromosomal deletions/full-arm losses were more common than gains. Diploidy/tetraploidy was detected in 2 cases and chromothripsis in 1. Anaplastic and recurrent tumors had more complex copy numbers aberrations, including numerous loci of loss of heterozygosity. Statistical significance however was not reached. Additional copy number aberrations characterize Os. Complex copy number profiles associate with aggressive morphology and recurrence. Citation Format: Steve Lowe, Scott Lindhorst, David Cachia, Adriana Olar. Complex copy number profiles in oligodendroglioma associate with anaplastic morphology and recurrence [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 2138.
Defining pain terms
Authors: R. H. de Fong
Journal: JAMA (1980)

THE MEANING of many terms we use in medicine can be interpreted in various ways, depending on who does the interpreting. Partly that is because some terms defy precise definition, partly because we use terms loosely, and partly because of differences in cultural and educational backgrounds. With the English language assuming the role of lingua franca, the possibility of misinterpretation is further compounded when medical terms are applied by physicians with limited fluency in English. Ethnic shadings and subtle differences in local meaning introduced by direct translation could well obscure the original author's true intent. In an amorphous field such as the care and study of pain—where words are colored by experience, tradition, culture, and surroundings—uniformity of verbal and written communication was thought to be well-nigh impossible. Yet it is vitally important to the patient suffering from pain that each attending physician understand precisely what other colleagues observed and elicited,
Abstract 1635: The histone demethylase KDM3A in Ewing Sarcoma metastasis
Authors: Marybeth Sechler, Janet Parrish, Paul Jedlicka
Journal: Cancer Research (2016)

Abstract This study aims to explore the roles and mechanisms of new candidates for therapeutic targeting in Ewing Sarcoma. Ewing Sarcoma is an aggressive pediatric malignancy of the bone and soft tissue, driven by EWS/Ets oncogenic fusions and characterized by high propensity for metastasis and poor clinical outcomes. We have identified the histone demethylase KDM3A as a novel tumor and metastasis promoter downstream of EWS/Fli1, the most common driver in this disease. Moreover, we have identified the cell surface protein, Melanoma Cell Adhesion Molecule (MCAM), as a potential important mediator of KDM3A action. Our data show that both KDM3A and MCAM depletion can inhibit growth and metastatic phenotypes. Additionally we explore the regulation of MCAM, showing that KDM3A may upregulate MCAM expression both through a direct as well as an indirect mechanism via the Ets1 transcription factor. Since both KDM3A and MCAM are pharmacologically targetable, understanding of this pathway could provide at least two new therapeutic targets in Ewing Sarcoma, and, importantly alternatives to drugging of EWS/Ets fusions, which to date has proven very difficult. Citation Format: Marybeth Sechler, Janet Parrish, Paul Jedlicka. The histone demethylase KDM3A in Ewing Sarcoma metastasis. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1635.
Environmental Influences on the Immune System and Allergic Reactions
Authors: N. Franklin Adkinson
Journal: Environmental Health Perspectives (1977)

Environmental interactions with the immune system may result in two types of adverse outcomes: immunodeficiency and immunopathology. Serious immunodeficiency most commonly results from ionizing radiation or as a recognized side effect of iatrogenic drug therapy, usually cancer chemotherapy. At present there is little basis for believing that biologically significant suppression of immune competence in man results from more subtle interactions with environmental agents. On the other hand, environmentally triggered immunopathology is a source of considerable morbidity and mortality. Additional research is needed in the following areas: (a) basic mechanisms of immunopathological reactions; (b) development of methods for accurately implicating or excluding immunological mechanisms in the etiology of hypersensitivity states; (c) development of methods for assessing in advance the potential immunogenicity of new industrial chemicals and occupational allergens; (d) identification of the risk factors which predispose to immunopathological outcomes when individuals are exposed to sensitizing chemicals or other "natural" allergens.
Lifetime Benefits and Costs of Intensive Therapy as Practiced in the Diabetes Control and Complications Trial
Journal: JAMA (1996)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Surgery of the Chest.
Journal: JAMA (1897)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal